BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29294072)

  • 1. Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach.
    Frymoyer A; Stockmann C; Hersh AL; Goswami S; Keizer RJ
    J Pediatric Infect Dis Soc; 2019 May; 8(2):97-104. PubMed ID: 29294072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
    Mehrotra N; Tang L; Phelps SJ; Meibohm B
    Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
    Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
    Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
    Lo YL; van Hasselt JG; Heng SC; Lim CT; Lee TC; Charles BG
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2626-32. PubMed ID: 20385872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.
    Kato H; Hagihara M; Nishiyama N; Koizumi Y; Mikamo H; Matsuura K; Yamagishi Y
    J Infect Chemother; 2017 Mar; 23(3):154-160. PubMed ID: 28017667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.
    Mulubwa M; Griesel HA; Mugabo P; Dippenaar R; van Wyk L
    Drugs R D; 2020 Jun; 20(2):105-113. PubMed ID: 32266599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
    Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
    Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
    Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.
    Bhongsatiern J; Stockmann C; Roberts JK; Yu T; Korgenski KE; Spigarelli MG; Desai PB; Sherwin CM
    Ther Drug Monit; 2015 Dec; 37(6):756-65. PubMed ID: 26562817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
    Chen Y; Wu D; Dong M; Zhu Y; Lu J; Li X; Chen C; Li Z
    Eur J Clin Pharmacol; 2018 Jul; 74(7):921-930. PubMed ID: 29602981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin is commonly under-dosed in critically ill children and neonates.
    Sosnin N; Curtis N; Cranswick N; Chiletti R; Gwee A
    Br J Clin Pharmacol; 2019 Nov; 85(11):2591-2598. PubMed ID: 31378957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
    Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
    Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of vancomycin target trough attainment with published dosing regimens in the neonatal intensive care unit population.
    Chung E; Lee SE; Abraham T; Saad NN; Gad A
    J Neonatal Perinatal Med; 2019; 12(1):21-27. PubMed ID: 30149480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of vancomycin individualized model-based dosing approach in neonates.
    Abouelkheir M; Almohaizeie A; Almutairi A; Almuhisen S; Alqahtani S; Alsultan A
    Pediatr Neonatol; 2023 May; 64(3):327-334. PubMed ID: 36581523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations.
    Reilly AM; Ding MX; Rower JE; Kiser TH
    J Clin Pharmacol; 2019 Jul; 59(7):997-1005. PubMed ID: 30776089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
    Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
    Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin prescription in neonates and young infants: toward a simplified dosage.
    Oudin C; Vialet R; Boulamery A; Martin C; Simon N
    Arch Dis Child Fetal Neonatal Ed; 2011 Sep; 96(5):F365-70. PubMed ID: 21378399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin Area Under the Curve Simplified.
    Lewis P
    Ther Drug Monit; 2018 Jun; 40(3):377-380. PubMed ID: 29494420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.
    Prybylski JP
    Clin Pharmacokinet; 2017 Mar; 56(3):263-272. PubMed ID: 27389404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.